Complement activation as a biomarker for Alzheimer's disease

M Aiyaz, MK Lupton, P Proitsi, JF Powell, S Lovestone - Immunobiology, 2012 - Elsevier
There is increasing evidence from genetic, immunohistochemical, proteomic and
epidemiological studies as well as in model systems that complement activation has an …
被引用次数：69 相关文章

Complement activation as a biomarker for Alzheimer's disease.

M Aiyaz, MK Lupton, P Proitsi, JF Powell… - …, 2011 - europepmc.org
There is increasing evidence from genetic, immunohistochemical, proteomic and
epidemiological studies as well as in model systems that complement activation has an …

Complement activation as a biomarker for Alzheimer's disease

M Aiyaz, MK Lupton, P Proitsi, JF Powell… - …, 2012 - kclpure.kcl.ac.uk
There is increasing evidence from genetic, immunohistochemical, proteomic and
epidemiological studies as well as in model systems that complement activation has an …

Complement activation as a biomarker for Alzheimer's disease

M Aiyaz, MK Lupton, P Proitsi, JF Powell, S Lovestone - Immunobiology, 2012 - infona.pl
There is increasing evidence from genetic, immunohistochemical, proteomic and
epidemiological studies as well as in model systems that complement activation has an …

Complement activation as a biomarker for Alzheimer's disease

M Aiyaz, MK Lupton, P Proitsi, JF Powell… - …, 2012 - pubmed.ncbi.nlm.nih.gov
There is increasing evidence from genetic, immunohistochemical, proteomic and
epidemiological studies as well as in model systems that complement activation has an …

[引用][C] Complement activation as a biomarker for Alzheimer's disease

M Aiyaz, MK Lupton, P Proitsi, JF Powell, S Lovestone - Immunobiology, 2012 - cir.nii.ac.jp
Complement activation as a biomarker for Alzheimer's disease | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …